Caris Life Sciences Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
1,846
- Stock Symbol
-
CAI
- Investments
-
5
- Share Price
-
$23.96
- (As of Thursday Closing)
Caris Life Sciences General Information
Description
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Contact Information
Website
www.carislifesciences.comCorporate Office
- 750 West John Carpenter Freeway
- Suite 800
- Irving, TX 75039
- United States
Corporate Office
- 750 West John Carpenter Freeway
- Suite 800
- Irving, TX 75039
- United States
Caris Life Sciences Timeline
Caris Life Sciences Stock Performance
As of 12-Nov-2026, Caris Life Sciences’s stock price is $23.96. Its current market cap is $6.87B with 287M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $23.96 | $24.49 | $14.19 - $36.50 | $6.87B | 287M | 4.7M | $0.34 |
Caris Life Sciences Financials Summary
As of 30-Sep-2026, Caris Life Sciences has a trailing 12-month revenue of $1.05B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 8,315,178 | 7,283,569 | ||
| Revenue | 1,048,129 | 812,033 | 412,260 | 306,128 |
| EBITDA | 135,715 | (5,117) | (190,074) | (272,062) |
| Net Income | 96,060 | (68,088) | (281,890) | (341,415) |
| Total Assets | 1,255,623 | 1,125,663 | 343,734 | 412,900 |
| Total Debt | 463,020 | 427,686 | 424,259 | 217,107 |
Caris Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Caris Life Sciences Comparisons
Industry
Financing
Details
Caris Life Sciences Competitors (16)
One of Caris Life Sciences’s 16 competitors is Personalis, a Formerly VC-backed company based in Fremont, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Personalis | Formerly VC-backed | Fremont, CA | ||||
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Oncimmune | Formerly VC-backed | Cambridge, MA | ||||
| GnuBIO | Formerly VC-backed | Cambridge, MA | ||||
| Complete Genomics | Formerly VC-backed | San Jose, CA |
Caris Life Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Caris Life Sciences Patents
Caris Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026217710-A1 | Immunotherapy vaccine | Pending | 08-Apr-2025 | ||
| WO-2026174323-A1 | Predicting methylation status | Pending | 14-Feb-2025 | ||
| WO-2026165288-A2 | Multi-task machine learning models for digital pathology | Pending | 29-Jan-2025 | ||
| WO-2026165288-A3 | Multi-task machine learning models for digital pathology | Pending | 29-Jan-2025 | ||
| WO-2025255578-A1 | Dual-modality models for digital pathology | Pending | 07-Jun-2024 | G06V10/82 |
Caris Life Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Caris Life Sciences Investments (5)
Caris Life Sciences’s most recent deal was a Buyout/LBO with Pharmatech. The deal was made on 01-May-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pharmatech | 01-May-2019 | Buyout/LBO | Other Healthcare Services | ||
| Phytel | 11-Feb-2010 | Later Stage VC | Enterprise Systems (Healthcare) | ||
| Molecular Profiling Institute | 02-Jul-2008 | Buyout/LBO | Laboratory Services (Healthcare) | ||
| PhyServe Physician Services | 21-Dec-2006 | PE Growth/Expansion | Practice Management (Healthcare) | ||
| Inform Diagnostics | 26-May-2005 | Buyout/LBO | Laboratory Services (Healthcare) |
Caris Life Sciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
40.91 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Caris Life Sciences Exits (3)
Caris Life Sciences’s most recent exit was on 11-Feb-2010 from Phytel. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Phytel | 11-Feb-2010 | Completed |
|
||
| PhyServe Physician Services | 21-Dec-2006 | Completed |
|
||
| Inform Diagnostics | 26-May-2005 | Buyout/LBO | Completed |
|
Caris Life Sciences FAQs
-
When was Caris Life Sciences founded?
Caris Life Sciences was founded in 2008.
-
Where is Caris Life Sciences headquartered?
Caris Life Sciences is headquartered in Irving, TX.
-
What is the size of Caris Life Sciences?
Caris Life Sciences has 1,846 total employees.
-
What industry is Caris Life Sciences in?
Caris Life Sciences’s primary industry is Biotechnology.
-
Is Caris Life Sciences a private or public company?
Caris Life Sciences is a Public company.
-
What is Caris Life Sciences’s stock symbol?
The ticker symbol for Caris Life Sciences is CAI.
-
What is the current stock price of Caris Life Sciences?
As of 12-Nov-2026 the stock price of Caris Life Sciences is $23.96.
-
What is the current market cap of Caris Life Sciences?
The current market capitalization of Caris Life Sciences is $6.87B.
-
What is Caris Life Sciences’s current revenue?
The trailing twelve month revenue for Caris Life Sciences is $1.05B.
-
Who are Caris Life Sciences’s competitors?
Personalis, Editas Medicine, Oncimmune, GnuBIO, and Complete Genomics are some of the 16 competitors of Caris Life Sciences.
-
What is Caris Life Sciences’s annual earnings per share (EPS)?
Caris Life Sciences’s EPS for 12 months was $0.34.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
